レンバチニブメシル酸塩（C型およびMIBK溶媒和物） API

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.

Lenvatinib is indicated for the treatment of the following cancerous conditions:5

Differentiated Thyroid Cancer (DTC)

• Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer

Renal Cell Carcinoma (RCC)

• First-line treatment, in combination with pembrolizumab, in adult patients with advanced renal cell carcinoma (RCC)
• Treatment of advanced renal cell carcinoma, in combination with everolimus, in adult patients who have previously tried ≥1 anti-angiogenic therapy

Hepatocellular Carcinoma (HCC)

• First-line treatment of patients with unresectable hepatocellular carcinoma

Endometrial Carcinoma

• Treatment of advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), in combination with pembrolizumab, in patients who have experienced disease progression following prior systemic therapy and are not candidates for curative surgery or radiation